In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 11, 2009, Pages 4915-4920

  Adam, Heather J ^a   Laing, Nancy M ^b   King, C Richard ^c   Lulashnyk, Ben ^b   Hoban, Daryl J ^a,b   Zhanel, George G ^b  

^a HEALTH SCIENCES CENTRE   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c TaiGen Biotechnology Co Ltd   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOFLOXACIN; MOXIFLOXACIN; NEMONOXACIN; QUINOLONE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ARTICLE; DRUG ACTIVITY; DRUG STRUCTURE; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; GRAM POSITIVE COCCI; IN VITRO STUDY; ISOLATION PROCEDURE; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS EPIDERMIDIS; STREPTOCOCCUS PNEUMONIAE;

ANTI-INFECTIVE AGENTS; BACTERIA; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; QUINOLONES;

EID: 70350279545     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00078-09     Document Type: Article

References (18)

1. Andersson, M. I., and A. P. MacGowan. 2003. Development of the quinolones. J. Antimicrob. Chemother. 51(Suppl. 1):1-11.
2. Barry, A. L., P. C. Fuchs, and S. D. Brown. 2001. In vitro activities of three nonfluorinated quinolones against representative bacterial isolates. Antimicrob. Agents Chemother. 45:1923-1927.
3. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Clinical and Laboratory Standards Institute. 2008. Performance standards for antimicrobial susceptibility testing. Eighteenth informational supplement. M100-S18. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Golding, G., J. Campbell, D. Spreitzer, J. Veyhl, K. Surynicz, and A. Simor. 2008. A preliminary guideline for the assignment of methicillin-resistant Staphylococcus aureus to a Canadian pulsed-field gel electrophoresis epidemic type using spa typing. Can. J. Infect. Dis. Med. Microbiol. 19:273-281.
6. Hsu, C. H., Y. M. Chen, and C. P. Chow. 2008. Systemic hypersensitivity of nemonoxacin, a novel potent broad-spectrum non-fluorinated quinolone, in guinea pigs, abstr. F1-2055. Abstr. Joint Meet. 48th Intersci. Conf. Antimicrob. Agents Chemother. and 46th Annu. Meet. Infect. Dis. Soc. Am.
7. Hsu, C. H., L. Lin, R. Leunk, and D. Reichart. 2008. In vivo efficacy of nemonoxacin in a mouse protection model, abstr. B1-1005. Abstr. Joint Meet. 48th Intersci. Conf. Antimicrob. Agents Chemotherapy and 46th Annu. Meet. Infect. Dis. Soc. Am.
8. Hsu, C. H., L. Lin, R. Leunk, and D. Reichart. 2008. In vivo efficacy of nemonoxacin in a mouse pulmonary infection model, abstr. B-056. Abstr. Joint Meet. 48th Intersci. Conf. Antimicrob. Agents Chemother. and 46th Annu. Meet. Infect. Dis. Soc. Am.
9. Lai, C. C., C. K. Tan, S. H. Lin, C. H. Liao, C. H. Chou, H. L. Hsu, Y. T. Huang, and P. R. Hsueh. 2009. Comparative in vitro activities of nemonoxacin, doripenem, tigecycline and 16 other antimicrobials against Nocardia brasiliensis, Nocardia asteroides and unusual Nocardia species. J. Antimicrob. Chemother. 64:73-78.
10. Mulvey, M. R., L. Chui, J. Ismail, L. Louie, C. Murphy, N. Chang, and M. Alfa. 2001. Development of a Canadian standardized protocol for subtyping methicillin-resistant Staphylococcus aureus using pulsed-field gel electrophoresis. J. Clin. Microbiol. 39:3481-3485.
11. Nichol, K. A., M. McCracken, M. R. DeCorby, K. Thompson, M. R. Mulvey, J. A. Karlowsky, D. J. Hoban, and G. G. Zhanel. 2009. Comparison of community-associated and health care-associated methicillin resistant Staphylococcus aureus in Canada: results from CANWARD 2007. Can. J. Infect. Dis. Med. Microbiol. 20:31A-36A.
12. Pankuch, G. A., K. Kosowska-Shick, P. McGhee, C. R. King, and P. Appelbaum. 2008. Comparative antistaphylococcal activity of nemonoxacin, a novel broad-spectrum quinolone, abstr. C1-189. Abstr. Joint Meet. 48th Intersci. Conf. Antimicrob. Agents Chemother. and 46th Annu. Meet. Infect. Dis. Soc. Am.
13. Peterson, L. R. 2001. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin. Infect. Dis. 33:S180-S186.
14. Simor, A., D. Boyd, A. Louie, A. McGeer, M. R. Mulvey, and B. Willey. 1999. Characterization and proposed nomenclature of epidemic strains of MRSA in Canada. Can. J. Infect. Dis. 10:333-336.
15. Tan, C. K., C. C. Lai, C. H. Liao, C. H. Chou, H. L. Hsu, Y. T. Huang, and P. R. Hsueh. 2009. Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. J. Antimicrob. Chemother. 64:428-429.
16. Van Rensburg, D. J., R. P. Perng, L. Lin, and H. Zhang. 2008. Efficacy and safety of nemonoxacin versus levofloxacin for the treatment of community-acquired pneumonia, abstr. L-678. Abstr. Joint Meet. 48th Intersci. Conf. Antimicrob. Agents Chemother. and 46th Annu. Meet. Infect. Dis. Soc. Am.
17. Wright, D. H., G. H. Brown, M. L. Peterson, and J. C. Rotschafer. 2000. Application of fluoroquinolone pharmacodynamics. J. Antimicrob. Chemother. 46:669-683.
18. Zhanel, G. G., J. A. Karlowsky, M. DeCorby, K. Nichol, A. Wierzbowski, P. J. Baudry, P. Lagace-Wiens, A. Walkty, F. Schweizer, H. Adam, M. McCracken, M. R. Mulvey, and D. J. Hoban. 2009. Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2007). Can. J. Infect. Dis. Med. Microbiol. 20:9A-19A.